Daratumumab Pilot Study Offers New Insights into ME/CFS

A new pilot study has added to the growing evidence that the immune system may play an important role in ME/CFS for some patients. Researchers investigated daratumumab, a medication that targets long-lived plasma cells, the immune cells responsible for producing antibodies.

Their hypothesis is that, in a subgroup of people with ME/CFS, these plasma cells may produce harmful autoantibodies that continue to disrupt normal body function after an infection.

The study enrolled 10 women with moderate to severe ME/CFS, who were followed for up to two years after treatment.

Six participants experienced substantial improvements in physical function, symptom severity, and daily activity levels, while four did not show significant clinical benefit. Researchers also observed that patients who improved had a greater temporary reduction in IgG antibody levels, supporting the idea that reducing antibody-producing plasma cells may be linked to symptom improvement.

While these findings are encouraging, it's important to remember that this was a small, open-label pilot study without a placebo group. That means the results cannot yet prove that daratumumab is an effective treatment for ME/CFS. Larger, randomized clinical trials will be needed to confirm these early findings.

Nevertheless, the study provides important support for ongoing research into the role of autoimmunity in ME/CFS and highlights a promising avenue for future treatment development.

Read the entire study here.